Bitter taste receptors (TAS2Rs) are expressed on human airway smooth muscle (HASM) and when activated markedly relax the muscle and dilate the airway. Utilization of this pathway, which is distinct from that of ?- agonists acting at ?2-adrenergic receptors (?2ARs), will provide a new class of direct bronchodilators for treating or preventing bronchospasm in asthma. The TAS2R14 subtype is highly expressed in HASM and is a prime target for developing a novel therapeutic agent. However, there are gaps in our knowledge about the molecular/cellular biology and physiology of HASM TAS2Rs, including how they couple to relaxation, the potential for tachyphylaxis due to short-term (receptor phosphorylation) and long-term (downregulation of receptor expression) events, and the potential to bias receptor signaling towards favorable signaling for asthma treatment. The broad, long-term objective of the Project is to improve our understanding of HASM TAS2R biology relevant to treating airway contraction in asthma. To fill these gaps in our knowledge, in Aim 1 we will define the mechanism by which TAS2Rs evoke relaxation, which we hypothesize is via inhibiting phosphorylation of the actin severing protein cofilin. Studies will be performed in cultured HASM cells derived from nonasthmatic as well as asthmatic donor lungs, the latter being important because of the potential for the disease to modify receptor function. Studies will include siRNA-based knockouts of cofilin, and the upstream components of the proposed pathway that link the receptor:G-protein:effector complex to cofilin.
In Aim 2, agonist-prompted phosphorylation of TAS2R14 by GRKs will be studied using whole cell phosphorylation and receptor purification experiments. To define the precise residues phosphorylated by GRKs, TAS2R14 will be mutated to substitute potential Ser/Thr phospho-acceptor sites with Ala, thus defining a bar-code for ?arrestin binding. The consequences of phosphorylation on ?arrestin conformation and intracellular receptor signaling, and HASM relaxation, will then be determined.
In Aim 3, a panel of TAS2R14 agonists will be utilized to determine the mechanisms by which a TAS2R agonist can be biased away from deleterious outcomes and towards advantageous outcomes in regards to asthma therapy. This endeavor will provide the basis for agonist-based ?tuning? of the receptor to be highly efficacious in bronchodilating and inhibiting HASM proliferation, but display little short- or long-term agonist-promoted desensitization or downregulation, such that clinical tachyphylaxis is not apparent. All three aims will utilize parallel physiological measurements of contraction and relaxation using nonasthmatic and asthmatic HASM cells, and an inflammatory precision-cut human lung slice model, in order to link biochemical events to clinically relevant physiological responses. Collectively, these studies will provide the basis for development of a novel class of direct bronchodilators which can be utilized alone, or in combination, with ?-agonists for the treatment of asthma.

Public Health Relevance

Asthma remains a significant health issue, affecting ~25 million individuals in the US. This project will study a new drug pathway that opens the constricted airway in asthma, thus providing a new means for better care.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL114471-07
Application #
9998005
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Noel, Patricia
Project Start
2013-07-15
Project End
2024-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
DUNS #
078816195
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Chaturvedi, Madhu; Schilling, Justin; Beautrait, Alexandre et al. (2018) Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. Trends Biochem Sci 43:533-546
Tliba, Omar; Panettieri Jr, Reynold A (2018) Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation. J Allergy Clin Immunol :
Pera, Tonio; Deshpande, Deepak A; Ippolito, Michael et al. (2018) Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines. FASEB J 32:862-874
Ojiaku, Christie A; Cao, Gaoyuan; Zhu, Wanqu et al. (2018) TGF-?1 Evokes Human Airway Smooth Muscle Cell Shortening and Hyperresponsiveness via Smad3. Am J Respir Cell Mol Biol 58:575-584
Kennedy, Joshua L; Koziol-White, Cynthia J; Jeffus, Susanne et al. (2018) Effects of rhinovirus 39 infection on airway hyperresponsiveness to carbachol in human airways precision cut lung slices. J Allergy Clin Immunol 141:1887-1890.e1
Komolov, Konstantin E; Benovic, Jeffrey L (2018) G protein-coupled receptor kinases: Past, present and future. Cell Signal 41:17-24
Lapadula, Dominic; Farias, Eduardo; Randolph, Clinita E et al. (2018) Effects of Oncogenic G?q and G?11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res :
Lotvall, Jan; Panettieri Jr, Reynold A (2018) Thank you and farewell after 15 years editing respiratory research. Respir Res 19:232
Panettieri, Reynold A; Pera, Tonio; Liggett, Stephen B et al. (2018) Pepducins as a potential treatment strategy for asthma and COPD. Curr Opin Pharmacol 40:120-125
Lo, Dennis; Kennedy, Joshua L; Kurten, Richard C et al. (2018) Modulation of airway hyperresponsiveness by rhinovirus exposure. Respir Res 19:208

Showing the most recent 10 out of 68 publications